Welcome!

News Feed Item

Circassia's ToleroMune® Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start of Short-Course Therapy

OXFORD, England and SAN ANTONIO, February 25, 2013 /PRNewswire/ --

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune® cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.  The results were presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio, USA on Sunday 24 February.

The phase II study originally measured improvements in nasal and ocular allergy symptoms (Total Rhinoconjunctivitis Symptom Score; TRSS) in 202 patients, following treatment with ToleroMune® therapy or placebo.  Two years after the start of the study, and having received no further ToleroMune® treatment, 50 of the original patients returned to reassess their symptoms while exposed to cat allergens.  The results show that at the end of the cat allergen challenge, patients who had previously been treated with four doses of ToleroMune® therapy over 12 weeks had a significant improvement in symptoms two years later, compared with placebo (p<0.05; 50.0% TRSS improvement on ToleroMune® treatment vs 14.9% on placebo). These patients also maintained a substantial reduction in symptoms throughout their entire exposure to cat allergens over the four day challenge (38.3% TRSS improvement vs 13.4% on placebo).  In addition, the results show that these patients maintained consistent symptom improvements both 12 and 24 months after the start of treatment. The ToleroMune® therapy was well tolerated with a safety profile comparable to placebo.  

Commenting on the results, co-author of the AAAAI conference presentation, Professor Mark Larché, Canada Research Chair in Allergy and Immune Tolerance, McMaster University and St. Joseph's Healthcare, Hamilton, said, "Sustaining such a substantial improvement in patients' allergy symptoms two years after the start of the study is remarkable.  Achieving this with a short course of just four doses is even more impressive.  These results suggest that ToleroMune® therapy has the potential to revolutionise treatment for cat allergy patients."

"These excellent clinical results are extremely encouraging, and strongly support Circassia's decision to progress to phase III at the end of last year," said Steve Harris, Circassia's CEO.  "Offering patients sustained symptom control without the need for ongoing treatment is an important objective for allergy therapy.  In this study, our ToleroMune® treatment reduced symptoms by two and a half to three times the level achieved by several other allergy therapies in similar studies, and maintained the improvement over a significant period, demonstrating its potential to greatly improve the lives of patients around the world."

About cat allergy

Allergies are a significant global health issue.  Allergic rhinoconjunctivitis (ARC) affects up to 30% of adults and 40% of children in developed countries, and its prevalence is rising.  ARC reduces quality of life and impacts school and work attendance and performance.  In Continental Europe and the USA, cat allergy is one of the most common forms of the disease, and affects 10 - 15% of those with ARC and / or asthma.  As cat dander is widespread in the human environment, and widely found in public buildings, patients with cat allergy may experience significant symptoms despite attempting to avoid exposure.  Current treatment options include temporary symptom suppression with antihistamines, corticosteroids and cromones, or long-term whole allergen immunotherapy, which can require treatment for three to five years and has the potential to induce life-threatening anaphylactic reactions.  

About ToleroMune®

Circassia's cat allergy treatment is based on the company's novel, proprietary ToleroMune® technology.  This uses rationally-designed combinations of synthetic peptides to generate regulatory T cells to control allergic responses and induce immune tolerance.  Circassia's ToleroMune® cat allergy treatment consists of seven peptides identified from the major cat allergen Fel d 1.  It has successfully completed a number of phase II studies, which demonstrate that courses of short, simple treatment can substantially reduce patients' symptoms and have a favourable safety profile.  In long-term follow up, patients' symptoms remained greatly improved two years after the start of the study, despite no further treatment after the initial four doses given over 12 weeks.  Circassia's cat allergy treatment entered phase III clinical testing in October 2012.  

About Circassia

Circassia was founded by a team of highly experienced biotechnology scientists and entrepreneurs.  The company is based in the UK on the Oxford Science Park, and its joint venture with McMaster University (Adiga Life Sciences Inc) is located in Hamilton, Canada.  Circassia's ToleroMune® technology was developed originally by scientists at Imperial College, London.  Having successfully completed five fundraising rounds, Circassia has raised approximately £105 million ($178 million) and is backed by a syndicate of world-class institutional investors, including Imperial Innovations and Invesco Perpetual.

Contacts
Steve Harris
CEO
Circassia
Tel: +44(0)1865-784574
http://www.circassia.co.uk
Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241


SOURCE Circassia

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
The best-practices for building IoT applications with Go Code that attendees can use to build their own IoT applications. In his session at @ThingsExpo, Indraneel Mitra, Senior Solutions Architect & Technology Evangelist at Cognizant, provided valuable information and resources for both novice and experienced developers on how to get started with IoT and Golang in a day. He also provided information on how to use Intel Arduino Kit, Go Robotics API and AWS IoT stack to build an application tha...
IoT generates lots of temporal data. But how do you unlock its value? You need to discover patterns that are repeatable in vast quantities of data, understand their meaning, and implement scalable monitoring across multiple data streams in order to monetize the discoveries and insights. Motif discovery and deep learning platforms are emerging to visualize sensor data, to search for patterns and to build application that can monitor real time streams efficiently. In his session at @ThingsExpo, ...
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
Ovum, a leading technology analyst firm, has published an in-depth report, Ovum Decision Matrix: Selecting a DevOps Release Management Solution, 2016–17. The report focuses on the automation aspects of DevOps, Release Management and compares solutions from the leading vendors.
Continuous testing helps bridge the gap between developing quickly and maintaining high quality products. But to implement continuous testing, CTOs must take a strategic approach to building a testing infrastructure and toolset that empowers their team to move fast. Download our guide to laying the groundwork for a scalable continuous testing strategy.
SYS-CON Events announced today that LeaseWeb USA, a cloud Infrastructure-as-a-Service (IaaS) provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LeaseWeb is one of the world's largest hosting brands. The company helps customers define, develop and deploy IT infrastructure tailored to their exact business needs, by combining various kinds cloud solutions.
Choosing the right cloud for your workloads is a balancing act that can cost your organization time, money and aggravation - unless you get it right the first time. Economics, speed, performance, accessibility, administrative needs and security all play a vital role in dictating your approach to the cloud. Without knowing the right questions to ask, you could wind up paying for capacity you'll never need or underestimating the resources required to run your applications.
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
StackIQ has announced the release of Stacki 3.2. Stacki is an easy-to-use Linux server provisioning tool. Stacki 3.2 delivers new capabilities that simplify the automation and integration of site-specific requirements. StackIQ is the commercial entity behind this open source bare metal provisioning tool. Since the release of Stacki in June of 2015, the Stacki core team has been focused on making the Community Edition meet the needs of members of the community, adding features and value, while ...
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it ...
SYS-CON Events announced today that Venafi, the Immune System for the Internet™ and the leading provider of Next Generation Trust Protection, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Venafi is the Immune System for the Internet™ that protects the foundation of all cybersecurity – cryptographic keys and digital certificates – so they can’t be misused by bad guys in attacks...
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of risk assessment, verification, and validation takes place to ensure business continuity during the migration to a new cloud platform.
It’s 2016: buildings are smart, connected and the IoT is fundamentally altering how control and operating systems work and speak to each other. Platforms across the enterprise are networked via inexpensive sensors to collect massive amounts of data for analytics, information management, and insights that can be used to continuously improve operations. In his session at @ThingsExpo, Brian Chemel, Co-Founder and CTO of Digital Lumens, will explore: The benefits sensor-networked systems bring to ...